Compare AVD & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVD | CMPX |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.8M | 927.5M |
| IPO Year | 1995 | 2020 |
| Metric | AVD | CMPX |
|---|---|---|
| Price | $2.64 | $1.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $12.00 | ★ $14.57 |
| AVG Volume (30 Days) | 196.8K | ★ 11.8M |
| Earning Date | 03-16-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $515,114,000.00 | N/A |
| Revenue This Year | $8.82 | N/A |
| Revenue Next Year | N/A | $934.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.05 | $1.61 |
| 52 Week High | $5.92 | $6.88 |
| Indicator | AVD | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 25.90 |
| Support Level | $2.30 | $1.61 |
| Resistance Level | $2.66 | $3.54 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 2.52 | 32.86 |
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. The company is a manufacturer of specialty solutions that develops and markets safe synthetic, biological, and biorational products for agricultural, commercial, and consumer uses. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.